High Dosage Lithium Treatment Induces DNA Damage and p57 Decrease.

Lithium salt is the first-line therapeutic option for bipolar disorder and has been proposed as a potential antitumoral drug. The effects of LiCl treatment were investigated in SH-SY5Y, a human neuroblastoma cell line and an in vitro model of dopaminergic neuronal differentiation. LiCl, at the dosage used in psychiatric treatment, does not affect cell proliferation, while at higher doses it delays the SH-SY5Y cell division cycle and for prolonged usage reduces cell viability. Moreover, the ion treatment affects DNA integrity as demonstrated by accumulation of p53 and γH2AX (the phosphorylated form of H2AX histone), two important markers of genome damage. p57, a CIP/Kip protein, is required for proper neuronal maturation and represents a main factor of response to stress including genotoxicity. We evaluated the effect of lithium on p57 levels. Unexpectedly, we found that lithium downregulates the level of p57 in a dose-dependent manner, mainly acting at the transcriptional level. A number of different approaches, mostly based on p57 content handling, confirmed that the CKI/Kip reduction plays a key role in the DNA damage activated by lithium and suggests the unanticipated view that p57 might be involved in DNA double-strand break responses. In conclusion, our study identified novel roles for p57 in the molecular mechanism of lithium at high concentration and, more in general, in the process of DNA repair.